The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells

被引:423
作者
Daniels, Tracy R.
Delgado, Tracie
Helguera, Gustavo
Penichet, Manuel L.
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Surg Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
transferrin receptor; receptor-mediated endocytosis; monoclonal antibodies; recombinant; antibodies; targeted immunotherapy; chemotherapy; immunotoxin; immunoconjugate;
D O I
10.1016/j.clim.2006.06.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Traditional anti-cancer treatments consist of chemotherapeutic drugs that effectively eliminate rapidly dividing tumor cells. However, in many cases chemotherapy fails to eliminate the tumor and even when chemotherapy is successful, its systemic cytotoxicity often results in detrimental side effects. To overcome these problems, many laboratories have focused on the design of novel therapies that exhibit tumor specific toxicity. The transferrin receptor (TfR), a cell membrane-associated glycoprotein involved in iron homeostasis and cell growth, has been explored as a target to deliver therapeutics into cancer cells due to its increased expression on malignant cells, accessibility on the cell surface, and constitutive endocytosis. The TfR can be targeted by direct interaction with conjugates of its ligand transferrin (Tf) or by monoclonal antibodies specific for the TfR. In this review we summarize the strategies of targeting the TfR in order to deliver therapeutic agents into tumor cells by receptor-mediated endocytosis. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:159 / 176
页数:18
相关论文
共 113 条
  • [1] Liposomal drug formulations - Rationale for development and what we can expect for the future
    Allen, TM
    [J]. DRUGS, 1998, 56 (05) : 747 - 756
  • [2] BARABAS K, 1992, J BIOL CHEM, V267, P9437
  • [3] EVIDENCE IN SUPPORT OF THE PLASMA-MEMBRANE AS THE TARGET FOR TRANSFERRIN-ADRIAMYCIN CONJUGATES IN K562 CELLS
    BARABAS, K
    SIZENSKY, JA
    FAULK, WP
    [J]. AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1991, 25 (03): : 120 - 123
  • [4] ANTITUMOR-ACTIVITY IN MICE OF AN IMMUNOTOXIN MADE WITH ANTI-TRANSFERRIN RECEPTOR AND A RECOMBINANT FORM OF PSEUDOMONAS EXOTOXIN
    BATRA, JK
    JINNO, Y
    CHAUDHARY, VK
    KONDO, T
    WILLINGHAM, MC
    FITZGERALD, DJ
    PASTAN, I
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) : 8545 - 8549
  • [5] SINGLE-CHAIN IMMUNOTOXINS DIRECTED AT THE HUMAN TRANSFERRIN RECEPTOR CONTAINING PSEUDOMONAS EXOTOXIN-A OR DIPHTHERIA-TOXIN - ANTI-TFR(FV)-PE40 AND DT388-ANTI-TFR(FV)
    BATRA, JK
    FITZGERALD, DJ
    CHAUDHARY, VK
    PASTAN, I
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (04) : 2200 - 2205
  • [6] BEJAOUI N, 1991, ANTICANCER RES, V11, P2211
  • [7] INFLUENCE OF CONJUGATION OF DOXORUBICIN TO TRANSFERRIN ON THE IRON UPTAKE BY K562-CELLS VIA RECEPTOR-MEDIATED ENDOCYTOSIS
    BERCZI, A
    RUTHNER, M
    SZUTS, V
    FRITZER, M
    SCHWEINZER, E
    GOLDENBERG, H
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 213 (01): : 427 - 436
  • [8] ADRIAMYCIN CONJUGATES OF HUMAN TRANSFERRIN BIND TRANSFERRIN RECEPTORS AND KILL K562 AND HL-60-CELLS
    BERCZI, A
    BARABAS, K
    SIZENSKY, JA
    FAULK, WP
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 300 (01) : 356 - 363
  • [9] KILLING OF K562 CELLS WITH CONJUGATES BETWEEN HUMAN TRANSFERRIN AND A RIBOSOME-INACTIVATING PROTEIN (SO-6)
    BERGAMASCHI, G
    CAZZOLA, M
    DEZZA, L
    SAVINO, E
    CONSONNI, L
    LAPPI, D
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1988, 68 (03) : 379 - 384
  • [10] Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil
    Beyer, U
    Roth, T
    Schumacher, P
    Maier, G
    Unold, A
    Frahm, AW
    Fiebig, HH
    Unger, C
    Kratz, F
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (15) : 2701 - 2708